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Background and objective: A single infective acute exacerbation of chronic bronchitis 
(AECB) has a sustained effect on health status. Although a number of clinical investigations 
have demonstrated the efficacy of antibiotics in AECB, increased bacterial resistance has caused 
concern about the efficacy of currently available antibiotic therapies. This subanalysis of a 
global noninterventional study aimed to evaluate the impact of AECB on the patient and the 
community and the effectiveness and safety of a treatment with moxifloxacin (MXF) tablets in 
daily life clinical practice in China.
Methods: This prospective, noninterventional, noncontrolled, multicenter observational study, 
which started in China in April 2004 and ended in February 2007, was part of the global GIANT 
study. Patients with a diagnosis of mild to severe AECB were treated with MXF tablets 400 mg 
for a period at the physician’s discretion. The observation period for each patient covered a com-
plete treatment period with MXF. For each patient, the physician documented data at an initial 
visit (baseline) and at least one follow-up visit. Data were collected on demography, diagnosis 
of infection, pretreatment, concomitant diseases and medications, MXF therapy, course of 
symptoms during investigations, and final assessment of therapy with respect to MXF.
Results: In the Chinese subset of the GIANT study, a total of 11,377 patients were included 
in the intention-to-treat/safety population. At the end of the initial treatment period, improve-
ment and recovery from infection was observed for 98.6% (n = 11,217/11,377) and 92.6% 
(n = 10,540/11,377) of all patients. After 1 week of treatment, 76.3% (n = 8681/11,377) of patients 
had recovered. Median time until improvement and recovery was 3.0 and 6.0 days, respectively. 
Correspondingly, in 95.8% (n = 10,903/11,377) of all patients, overall effectiveness during the 
initial treatment period with MXF was assessed as “very good” or “good”. Compared with the 
last AECB, the number of days with impact on daily-life activities and the number of nights with 
sleep disturbances decreased from 3.0 to 2.0 (median) and from 2.0 to 1.0 (median), respectively. 
In general, MXF treatment was very well tolerated, with physician’s overall assessment of toler-
ability as “good” or “very good” in 95.2% (n = 10,834/11,377) of patients. The incidence rate of 
adverse events and adverse drug reactions was 0.82% (n = 93) and 0.67% (n = 76), respectively. 
The most frequent adverse events were gastrointestinal disorders such as nausea (0.31%, n = 35) 
and vomiting (0.19%, n = 22), which were mostly drug-related. One individual serious adverse 
event (dyspnea) occurred during the observation period, which was assessed as drug-related.
Conclusion: MXF was effective and well tolerated in patients suffering from AECB. The fast speed 
of the drug’s onset of action was associated with rapid improvement of clinical parameters.
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Introduction
Chronic bronchitis is a clinical diagnosis in patients present-
ing with persistent cough and excessive secretion of mucus 
on most days for at least 3 consecutive months in 2 consecu-
tive years.1 Patients presenting clinical symptom of chronic 
bronchitis are a heterogeneous group in terms of the severity 
of their condition. Airflow obstruction is present to a variable 
degree, and emphysema may or may not be present.
A single infective exacerbation of chronic bronchitis 
(AECB) has a sustained effect on health status. The recovery 
period is long even in patients who have no further exacerba-
tions.2 These episodes contribute to morbidity, mortality and 
diminished quality of life,3 but their cause can be difficult to 
identify and may include air pollutants, allergens and viruses 
as well as bacterial pathogens. The bacterial species isolated 
most frequently from the sputum of patients with AECB 
include Haemophilus influenzae, Streptococcus pneumoniae 
and Moraxella catarrhalis.4
A number of clinical investigations have demonstrated 
the efficacy of antibiotics in AECB, but the causative patho-
gen is only rarely identified in clinical practice. Treatment 
is therefore usually empirical, and needs to cover the most 
likely pathogens. Increased bacterial resistance has caused 
concern about the efficacy of currently available antibiotic 
therapies. Failure to treat appropriately with an antibacterial 
that eradicates the pathogen quickly is associated with persis-
tent airway inflammation, and can increase the requirement 
for hospitalization and repeated course of therapy.
Moxifloxacin is an 8-metoxifluoroquinolone with a broad 
spectrum of antibacterial activity; it is effective against both 
Gram-positive and Gram-negative pathogens, atypical patho-
gens and anaerobic bacteria, including many drug-resistant 
bacteria.
The data presented here are the Chinese data from 
GIANT, a global noninterventional study, aimed to evaluate 
the impact of AECB on the patient and the community and 
the effectiveness and safety of treatment with moxifloxacin 
in daily routine practice.
Materials and methods
study design
The data presented were a subanalysis on the Chinese data 
of the global GIANT postmarketing surveillance study – a 
prospective, noninterventional, noncontrolled, multicenter 
study. The study was carried out in China between April 2004 
and February 2007. Patients with a diagnosis of mild to severe 
AECB who are prescribed moxifloxacin in daily life clini-
cal practice were documented. Moxifloxacin administration 
and dose were decided by the attending physician. The 
observation period for each patient covered a complete 
treatment period with moxifloxacin. For each patient, the 
physician documented data at an initial visit (baseline) and 
at least one follow-up visit. No additional diagnostic or 
monitoring procedures were applied to patients. Observa-
tion parameters are demography, AECB history (including 
treatment of last AECB, and impact on the patient), current 
chronic bronchitis, general and specific concomitant diseases, 
moxifloxacin therapy, and concomitant medication. Effec-
tiveness parameters include course of symptoms, duration 
until improvement and recovery, and overall assessment of 
effectiveness by patient and physician. Safety parameters 
include adverse events (AEs), adverse drug reactions (ADRs) 
and global assessment of tolerability.
Based on the symptom assessments by the physician at 
the start of therapy and at the last follow-up visit, calculations 
were performed for the course of the symptoms fever, dys-
pnea, cough, sputum volume, chest discomfort, and fatigue 
as well as for the course of sleep disturbance. A symptom 
was categorized as “relieved” if assessed as “none” or “no” 
at the last follow-up, as “improved” if assessed with a better 
category at the last follow-up compared to the start of therapy, 
as “unchanged” if assessments did not change, and as “wors-
ened” assessed with a worse category at the last follow-up 
compared to the start of therapy. Safety analysis included 
tabulation of type (using MedDRA coding) and frequency of 
all drug-related and nondrug-related AEs. The seriousness, 
action taken, and outcome of events were described.
Data analysis
The analysis was based on the intention-to-treat (ITT) 
population. Descriptive analyses of the data were performed 
using summary statistics for categorical and quantitative 
data. Continuous data were described by mean, SD, mini-
mum, 1, 5, 25, 75, 95, 99 percentiles, median, maximum, 
and number of nonmissing values. In addition, continu-
ous data were categorized in a clinically meaningful way. 
Categorical data including categories of continuous data 
were presented in frequency tables. If applicable, stratified 
frequency tables contained column percent and row per-
cent. Number of patients with missing data was presented 
as a separate category. Percentages were calculated as a 
proportion of each category including the category miss-
ing values. In defined cases, percentages were calculated 
based on non-missing values or for a predefined category. 
In summary tables of the report, the category “missing” 
was in general not listed.Clinical Epidemiology 2010:2 17
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study population
iTT population/safety population
The definitions of the ITT and safety population were iden-
tical in this study. Patients were included in the ITT/safety 
population if it was documented that they took at least one 
dose of moxifloxacin. A total of 11,454 patients were enrolled 
in this observational study. The first patient entered the study 
on April 24, 2004. The last visit of the last patient was on 
February 13, 2007. In summary, a total of 11,377 patients 
were valid for the ITT/safety population.
Results
Demographics
11,377 patients were included in the statistical analysis. 
More male than female patients (n = 7486/11,377, 65.8% vs 
n = 3885/11,377, 34.1%) were documented during the study 
(6 patients had missing data on sex). Almost all patients 
were described to be of Asian origin (n = 11,280/11,377, 
99.1%). Age ranged from 15 to 103 years, mean age was 
59.7 ± 15.1 years, and median age was 60.9 years. Male 
patients were on average (mean) 4.2 years older than 
female patients. Mean height was 167.1 ± 7.6 cm and mean 
weight 63.5 ± 10.5 kg. Mean body mass index was 22.6 ± 
2.9 kg/m2. About half of all patients (n = 5905/11,377, 
51.9%) were current smokers (n = 3106/11,377, 27.3%) or 
past smokers (n = 2799/11,377, 24.6%), whereas 47.5% 
(n = 5404/11,377) of patients were nonsmokers. Chronic 
bronchitis was diagnosed in 16.2% (n = 1846/11,377), 
38.0% (n = 4238/11,377), 21.4% (n = 2430/11,377), and 
22.4% (n = 2553/11,377) of the patients 1 year, 1 to 
5 years, 5 to 10 years, and 10 years prior to study start, 
respectively (Table 1).
At baseline (initial visit), the majority of patients 
(n = 7350/11,377, 64.6%) had one or more concomitant 
diseases relevant to AECB. The most frequently reported 
concomitant diseases by system organ class were cardiac 
diseases (n = 4255/11,377, 37.4%), thoracic and/or medi-
astinal diseases (n = 1775/11,377, 15.6%), and infections 
(n = 1638/11,377, 14.4%). More than one-quarter of the 
patients (n = 3220/11,377, 28.3%) suffered from only one con-
comitant disease, whereas two or more concomitant diseases 
were found in 36.3% (n = 4130/11,377) of patients. The most 
frequently reported concomitant pulmonary diseases were 
COPD (n = 4574/11,377, 40.2%), followed by emphysema 
(n = 3550/11,377, 31.2%). The most prevalent concomitant 
cardiac diseases were cor pulmonale (n = 1729/11,377, 
15.2%), cardiac ischemia (n = 1229/11,377, 10.8%), and heart 
insufficiency (n = 990/11,377, 8.7%) (Figure 1).
Table 1 Demographic and other baseline characteristics
Patients (N = 11,377)  
Sex
  Male 7486 (65.8%)
  Female 3885 (34.1%)
  Missing 6 (0.1%)
Race
  Asian 11,280 (99.1%)
  Other 93 (0.8%)
  Missing 4 (0.1)
Age (years)
  45 2028 (17.8%)
  45 and 65 4626 (40.7%)
  65 4494 (39.5%)
  Missing 229 (2.0%)
Nicotine consumption
  smoker 5905 (51.9%)
  nonsmoker 5404 (47.5%)
Duration of chronic bronchitis
  1 year 1846 (16.2%)
  1 to 5 years 4238 (38.0%)
  5 to 10 years 2430 (21.4%)
  10 years 2553 (22.4%)
Severity
  Mild 2319 (20.4%)
  Moderate 7394 (65.0%)
  severe 1608 (14.1%)
Treatments
Almost all patients started therapy with the approved dose of 
400 mg moxifloxacin once daily (n = 11,331/11,377, 99.6%). In 
five individual patients, an initial daily dose of 600 mg (n = 1) or 
800 mg (n = 4) was given. Moxifloxacin was administered to the 
majority of patients for periods of 5 (n = 4619/11,377, 40.6%), 
6 (n = 2947/11,377, 25.9%), and 7 (n = 1468/11,377, 12.9%) 
days. Following stratified analyses, duration of therapy was 
found to be related to the severity of infection: moxifloxacin was 
administered for a longer period in patients with severe AECB 
(7 days, median) than in patients with moderate (6 days, median) 
or mild exacerbation (5 days, median). The most commonly 
administered concomitant medications relevant to the chronic 
bronchitis treatment were “mucolytics” (n = 2958/11,377, 
26.0%), followed by “xanthines” (n = 1991/11,377, 17.5%), 
anti-infectives (n = 1172/11,377, 10.3%).
Effectiveness results
At the end of the observation period, mainly positive assess-
ments were given: for 95.8% (n = 10,903/11,377) of patients Clinical Epidemiology 2010:2 18
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effectiveness was rated as “very good” or “good”, while in 
2.7% (n = 303/11,377) and 0.7% (n = 83/11,377) of patients 
effectiveness was rated as “sufficient” and “insufficient”. Phy-
sicians were “very satisfied” or “satisfied” with the therapeutic 
effect in 98.1% (n = 11,165/11,377) of patients. Therapeutic 
effect was rated as “not satisfied” for 1.8% (n = 205/11,377) 
of patients. 97.4% (n = 11,079/11,377) of the patients were 
“very satisfied” or “satisfied” with the therapeutic effect, while 
2.5% (n = 284/11,377) were “not satisfied” (Table 2).
The mean duration until improvement was 3.2 ± 1.4 days, 
whereas the mean duration until recovery was 6.2 ± 2.2 days, 
with medians of 3.0 and 6.0 days, respectively. The range for 
improvement was from 1 to 23 days and for recovery from 
1 to 30 days. For approximately three-quarters of patients 
(n = 8248/11,377, 72.5%), an improvement was seen within 
3 days of treatment; in 93.8% (n = 10,672/11,377) of patients, 
an improvement was seen within 5 days of therapy. More 
than three-quarters (n = 8681/11,377, 76.3%) of all patients, 
recovered within 1 week of treatment (Figure 2).
For most patients, only one follow-up visit was docu-
mented. The last follow-up visit (first or second follow-up 
visit) was 7.0 days (median) after start of moxifloxacin ther-
apy. Patient symptoms documented at start of moxifloxacin 
therapy reflected a typical profile associated with AECB. At 
the last follow-up visit, a relevant reduction in all recorded 
symptoms was observed compared with the initial visit. 
The majority of patients experienced a change in symptoms 
from the initial visit to the last follow-up visit, described as 
“relieved” or “improved” (Figure 3).
Tolerability results
An overall assessment by physicians of tolerability of 
moxifloxacin treatment for each patient was made at the 
end of the initial treatment period. In general, moxifloxa-
cin treatment was considered to be well tolerated, rated in 
95.2% (n = 10,834/11,377) of patients as “very good” and 
“good”. For 4.2% (n = 481/11,377) of patients, tolerability 
was assessed to be “sufficient”. The category “insufficient” 
was given for 0.4% (n = 50/11,377) of patients. No rel-
evant differences were found when data were stratified by 
sex, age, AECB symptoms, and severity of the disorder 
(Figure 4).
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Figure 1 Concomitant diseases occurring in study patients.
Table 2 Effectiveness results at the end of the observation 
period
Physician’s effectiveness assessment
Very  
good
good Sufficient Insufficient Missing
6685  
(58.8%)
4218 
(37.1%)
303 
(2.7%)
83 
(0.7%)
88 
(0.8%)
Physician’s assessment of therapeutic effect
Total  
(n = 11,377)
Very  
satisfied
Satisfied not 
satisfied
Missing
5945  
(52.3%)
5220 
(45.9%)
205  
(1.8%)
7  
(0.1%)
Patient’s assessment of therapeutic effect
Very  
satisfied
Satisfied not 
satisfied
Missing
   5574  
(49.0%)
5505  
(48.4%)
287  
(2.5%)
11  
(0.1%)
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In summary, 147 events were reported in 93 patients. 
The majority of outcomes of all AEs were categorized as 
“resolved” or “improved” (Table 3).
One individual subject experienced a treatment-emergent 
serious AE (SAE) which was also assessed as drug-related 
(serious adverse drug reactions, SADR). The SADR (dys-
pnea) required hospitalization/prolongation of hospitalization 
and was resolved at the end of the observation period.
safety results
AEs occurred in 0.82% (n = 93/11,377) of patients during 
the observation period. The most frequently reported events 
were classed as “gastrointestinal disorders”, followed by 
“nervous system disorders” and “psychiatric disorders”. 
During the initial treatment period, symptoms such as nau-
sea (n = 35/11,377, 0.3%), vomiting (n = 22/11,377, 0.2%), 
and dizziness (n = 12/11,377, 0.1%) were predominant. Clinical Epidemiology 2010:2 20
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Discussion
AECB are a major cause of morbidity and mortality. Bacte-
rial pathogens are implicated in about half the episodes of 
AECB. Empirical antibacterials have a significant benefit in 
AECB; however, several recent developments have consider-
ably complicated antibacterial choice for this condition. New 
fluoroquinolone antibacterials introduced in the last decade 
are theoretically well suited for the treatment of AECB, as 
the in vitro antimicrobial spectrum of these drugs includes 
all the major pathogens involved.
The pharmacokinetic and pharmacodynamic properties 
of the new fluoroquinolones are superior to many other 
antibacterials used to treat AECB. Patients with AECB 
are a heterogeneous population who should be stratified 
in order to choose appropriately empirical antibacterial 
therapy. It is important to consider that bacterial resistance 
varies geographically at national, regional and community 
levels. Currently, fluoroquinolone resistance in respiratory 
pathogens is low, but there are strong links between rates 
of consumption and resistance.5 Significant relationships 
between increased fluoroquinolone use and reduced percent-
age susceptibility have also been demonstrated for a group 
of 11 bacterial pathogens (P  0.05).6 The studies for the 
new fluoroquinolone, moxifloxacin, have demonstrated that 
mutations in the target genes require more than one mutation. 
Theoretically, this requirement, in combination with the 
favorable pharmacokinetic and pharmacodynamic properties 
of fluoroquinolones (large AUIC and Cmax to MIC90 ratios), 
should delay the emergence of resistance to moxifloxacin.
A single strategy for antibacterial therapy for all epi-
sodes of AECB is therefore likely to lead to inadequate or 
excessive antibacterial treatment in many patients. Recently, 
a stratification approach to antibacterial therapy of AECB has 
been advocated.7,8 Significant risk factors that predict poor 
outcome of AECB episodes and failure of antibacterial treat-
ments have been recently identified. These risk factors include 
exacerbations characterized by multiple symptoms (increased 
dyspnea, sputum production and sputum purulence), older 
age (65 years), underlying severe obstructive lung disease, 
and frequent (4) exacerbations in the previous year and the 
presence of coexistent cardiac disease.7–9
In our study, chronic bronchitis was diagnosed in 
16.2% (n = 1843/11,377), 38.0% (n = 4323/11,377), 21.4% 
(n = 2435/11,377), and 22.4% (n = 2548/11,377) of the patients 
1 year, 1 to 5 years, 5 to 10 years, and more than 10 years 
prior to study start. Stratified analysis revealed that in subgroups 
with male patients, greater proportions of patients with longer 
duration of AECB were observed compared to subgroups with 
female patients. Other analyses indicated that in subgroups 
with older patients (65 years), unemployed patients and 
past smokers comparatively, greater proportions of patients 
with longer duration of AECB were observed compared with 
younger patients (65 years), employed patients, and cur-
rent/nonsmokers. In the 12-month period prior to study start, 
46.9% (n = 5336/11,377) of patients had one or two episodes of 
AECB, whereas three or more episodes were reported in 38.1% 
(n = 4335/11,377) of patients. Comparing these data to a similar 
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Figure 4 Physicians’ overall assessment of tolerability.
Table 3 Patient-based incidence rate of adverse events
  N = 11,377 n (%)
Any adverse events 93 (0.82)
Adverse drug reaction 76 (0.67)
serious adverse events 1 (0.01)
serious adverse drug reaction 1 (0.01)Clinical Epidemiology 2010:2
Clinical Epidemiology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-epidemiology-journal
Clinical Epidemiology is an international, peer-reviewed, open access 
journal focusing on disease and drug epidemiology, identification of 
risk factors and screening procedures to develop optimal preventative 
initiatives and programs. Specific topics include: diagnosis, prognosis, 
treatment, screening, prevention, risk factor modification, systematic 
reviews, risk & safety of medical interventions, epidemiology & 
biostatical methods, evaluation of guidelines, translational medicine, 
health policies & economic evaluations. The manuscript management 
system is completely online and includes a very quick and fair peer-
review system, which is all easy to use.
21
GIANT with moxifloxacin Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
analysis of European data of the GIANT study, more European 
patients suffered from chronic bronchitis for more than 10 years, 
the proportion of female patients and patients 65 years was 
higher, and fewer patients were nonsmokers.10
At the end of the observation period, mainly positive 
assessments were given: for 95.8% (n = 10,903/11,377) of 
patients effectiveness was rated as “very good” or “good”. 
The data show that physicians were “very satisfied” or “satis-
fied” with the therapeutic effect in 98.1% (n = 11,165 /11,377) 
of patients. Besides, moxifloxacin treatment was considered 
to be well tolerated, rated in 95.2% (n = 10,834/11,377) of 
patients as “very good” and “good”. AEs occurred in 0.82% 
(n = 93/11,377) of patients during the observation period. 
The majority of outcomes of all AEs were categorized as 
“resolved” or “improved”. Interestingly, Chinese physicians 
reported fewer adverse events than their European colleagues 
(2.6% of European patients suffered from an adverse event).4 
The results of this noninterventional study are consistent with 
the findings from prior randomized controlled trials, showing 
that AECB treatment with moxifloxacin at a dose of 400 mg 
is highly effective. Compared with other standard antibiotic 
therapies, treatment with moxifloxacin clearly resulted in 
higher patient and physician satisfaction.
The study included a large number of the AECB patients 
in China treated with moxifloxacin and was conducted under 
daily practice conditions. Patient recall may have limited 
the results of previous AECB treatment for number of days 
for which daily-life activities were affected and the number 
of nights with sleep disturbance. Other potential limitations 
are the open-label, noncontrolled design of the study and 
the lack of bacteriological testing to confirm diagnoses. In 
general, the high effectiveness and safety of moxifloxacin 
was demonstrated in the treatment of acute exacerbation of 
chronic bronchitis, which is identical to most of the results 
from randomized, controlled studies.4,11,12
Conclusion
In conclusion, moxifloxacin was efficacious and well tol-
erated in Chinese patients suffering from AECB. The fast 
speed of the drug’s onset of action was associated with rapid 
improvement of clinical parameters.
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